Mari Kirsten

TL;DR: Human rotvirus vaccine significantly reduced the incidence of severe rotavirus gastroenteritis among African infants during the first year of life.

TL;DR: IBI is an effective treatment in haemangiomas and vascular malformation lesions, obviating the need for invasive primary surgery or systemic treatment regimens in 80% of cases, and allowing for limited need of secondary surgical or adjunctive procedures in cases with a moderate result.

TL;DR: Rotarix™ vaccine demonstrated efficacy against severe gastroenteritis caused by diverse circulating rotavirus types, adding to a growing body of evidence supporting heterotypic protection provided by Rotarix’.

TL;DR: Rarix is associated with significant reductions in severe gastroenteritis episodes through 2 years of life among South African children, and further research is needed to determine the optimal dosing schedule of Rotarix in providing long-term protection against rotavirus illness in African children.

TL;DR: The risk of intussusception in the 21 days after the first or second dose of RV1 was not higher than the background risk among South Africa infants.